IN2014DN09392A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09392A
IN2014DN09392A IN9392DEN2014A IN2014DN09392A IN 2014DN09392 A IN2014DN09392 A IN 2014DN09392A IN 9392DEN2014 A IN9392DEN2014 A IN 9392DEN2014A IN 2014DN09392 A IN2014DN09392 A IN 2014DN09392A
Authority
IN
India
Prior art keywords
compounds
essentially pure
xxv
stimulating
formulas
Prior art date
Application number
Other languages
English (en)
Inventor
Walter A Shaw
Stephen W Burgess
Shengrong Li
David T Hickman
Maria Pilar Lopez-Deber
Original Assignee
Avanti Polar Lipids Inc
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Polar Lipids Inc, Ac Immune Sa filed Critical Avanti Polar Lipids Inc
Publication of IN2014DN09392A publication Critical patent/IN2014DN09392A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06Fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN9392DEN2014 2012-04-12 2013-04-12 IN2014DN09392A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623393P 2012-04-12 2012-04-12
US13/842,424 US9241988B2 (en) 2012-04-12 2013-03-15 Disaccharide synthetic lipid compounds and uses thereof
PCT/US2013/036425 WO2013155448A1 (en) 2012-04-12 2013-04-12 Disaccharide synthetic lipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09392A true IN2014DN09392A (enExample) 2015-07-17

Family

ID=49325307

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9392DEN2014 IN2014DN09392A (enExample) 2012-04-12 2013-04-12

Country Status (9)

Country Link
US (2) US9241988B2 (enExample)
EP (2) EP2836499B1 (enExample)
JP (3) JP6271510B2 (enExample)
CN (2) CN104470938B (enExample)
CA (1) CA2870008C (enExample)
DK (1) DK3674309T3 (enExample)
ES (2) ES2787876T3 (enExample)
IN (1) IN2014DN09392A (enExample)
WO (1) WO2013155448A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3191123B1 (en) * 2014-09-12 2020-06-03 Bestewil Holding B.v. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
EP3069729A1 (en) * 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016149417A1 (en) * 2015-03-17 2016-09-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
US20220339282A1 (en) * 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2024064783A1 (en) 2022-09-21 2024-03-28 Wisconsin Alumni Research Foundation Compositions and methods to enhance therapeutic efficacy of cancer therapies
WO2024151642A1 (en) * 2023-01-09 2024-07-18 University Of Maryland, Baltimore Engineered anti-nociceptive-los competitive tlr4 ligands and methods for treating pain while maintaining immunosufficiency

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066794A (en) 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
JP2535048B2 (ja) 1988-02-29 1996-09-18 第一製薬株式会社 新規ジサッカライド誘導体及びその塩
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体
AU679970B2 (en) 1993-09-07 1997-07-17 Suntory Limited Novel disaccharide derivative
JP3967769B2 (ja) * 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
JPH10152497A (ja) * 1996-09-30 1998-06-09 Otsuka Pharmaceut Factory Inc ヘリコバクター・ピロリのリピドa
KR100682154B1 (ko) * 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
CA2333578C (en) * 1998-07-14 2010-11-16 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
CA2396744C (en) * 1999-11-15 2011-07-12 Biomira, Inc. Synthetic lipid-a analogs and uses thereof
BR0110975A (pt) * 2000-05-19 2004-03-23 Corixa Corp Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
CN1907289A (zh) * 2000-05-19 2007-02-07 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
US8563523B2 (en) 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative
PT2222710T (pt) * 2007-12-24 2016-11-02 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof

Also Published As

Publication number Publication date
JP2018070652A (ja) 2018-05-10
CN104470938B (zh) 2017-07-28
JP6764396B2 (ja) 2020-09-30
CN104470938A (zh) 2015-03-25
DK3674309T3 (da) 2024-11-25
ES2992314T3 (es) 2024-12-11
CA2870008A1 (en) 2013-10-17
CN107412766A (zh) 2017-12-01
EP3674309B1 (en) 2024-09-11
EP2836499A4 (en) 2015-11-25
US20160136271A1 (en) 2016-05-19
WO2013155448A1 (en) 2013-10-17
EP2836499B1 (en) 2020-02-26
JP2015512946A (ja) 2015-04-30
CA2870008C (en) 2021-05-04
EP2836499A1 (en) 2015-02-18
JP2020147579A (ja) 2020-09-17
US20130273149A1 (en) 2013-10-17
JP7189906B2 (ja) 2022-12-14
ES2787876T3 (es) 2020-10-19
HK1207383A1 (en) 2016-01-29
JP6271510B2 (ja) 2018-01-31
US10143744B2 (en) 2018-12-04
US9241988B2 (en) 2016-01-26
EP3674309A1 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
IN2014DN09392A (enExample)
PH12016501151A1 (en) Nrf2 regulators
MX365614B (es) Composiciones utiles para tratar trastornos relacionados con kit.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
PH12014502350A1 (en) Mixtures, methods and compositions pertaining to conductive materials
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
GB0917002D0 (en) Improved shigella blebs
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
IN2014DN08481A (enExample)
MX2015005944A (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2021004211A (es) Composiciones vacuna.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IN2014DN06104A (enExample)
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MX2013000793A (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
PH12017500836A1 (en) Transdermal formulations
MX2018011162A (es) Metodos de purificacion de colageno 7.
SG10201900541QA (en) Derivatives of xanthone compounds
IN2014DN08412A (enExample)
MX2016000313A (es) Estabilizadores de luz novedosos.
IN2013MU03641A (enExample)
IN2014DN09584A (enExample)